Roivant Sciences Ltd. (ROIVW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Roivant Sciences Ltd. (ROIVW) trades at $2.75. Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company focused on developing medicines for various therapeutic areas. Market cap: $1.97B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ROIVW: ROIVW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ROIVW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on ROIVW.
How is this calculated? →Roivant Sciences Ltd. (ROIVW) Healthcare & Pipeline Overview
Roivant Sciences Ltd., founded in 2014, is a biopharmaceutical company focused on developing and commercializing therapies for a range of diseases, including solid tumors, sickle cell disease, and dermatological conditions. With a market cap of $1.97B, Roivant operates in the competitive biotechnology sector, emphasizing innovation and strategic partnerships.
What Is the Investment Thesis for ROIVW?
Roivant Sciences presents a compelling investment thesis based on its diversified pipeline and innovative business model. The company's hub-and-spoke structure allows for focused development efforts across multiple therapeutic areas, mitigating risk. Key value drivers include successful clinical trial outcomes and regulatory approvals for its lead drug candidates. Roivant's gross margin of 91.2% indicates strong potential for profitability upon commercialization of its products. However, the company's negative P/E ratio of -24.16 and profit margin of -6079.9% reflect its current stage of development and ongoing investments in research and development. Investors should monitor clinical trial data and regulatory milestones to assess the company's progress.
Based on FMP financials and quantitative analysis
ROIVW Key Highlights
Market capitalization of $1.97B reflects investor valuation of Roivant's pipeline and technology.
- Gross margin of 91.2% indicates strong potential profitability upon successful commercialization of drug candidates.
- Negative P/E ratio of -24.16 reflects the company's current investment phase and lack of profitability.
- Profit margin of -6079.9% highlights significant R&D expenses and operational costs associated with drug development.
- Roivant's diversified pipeline targets multiple therapeutic areas, reducing reliance on a single product or indication.
Who Are ROIVW's Competitors?
ROIVW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABCM Abcam plc | $23.99 | +0.04% | $5.52B | 46 |
| ALPN Alpine Immune Sciences, Inc. | $64.97 | +0.02% | $4.46B | 57 |
| BPMC Blueprint Medicines Corporation | $129.46 | +0.14% | $8.36B | 46 |
| CERE Cerevel Therapeutics Holdings, Inc. | $44.96 | +0.74% | $8.19B | 46 |
| IMGN ImmunoGen | $31.23 | +0.02% | $8.73B | 46 |
| GLPG Galapagos NV | $27.98 | +1.71% | $1.84B | 70 |
| VCEL Vericel Corporation | $42.11 | -3.35% | $2.16B | 94 |
| HRMY Harmony Biosciences Holdings, Inc. | $38.32 | -4.04% | $2.22B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ROIVW's Key Strengths?
Innovative hub-and-spoke business model.
- Diversified pipeline of drug candidates.
- Strong gross margin potential.
- Experienced management team.
What Are ROIVW's Weaknesses?
Negative P/E ratio and profit margin.
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- High R&D expenses.
What Could Drive ROIVW Stock Higher?
Clinical trial results for lead drug candidates in oncology and dermatology. (2026 Q3-Q4)
- Regulatory submissions and potential approvals for key pipeline assets. (2026-2027)
- Expansion of strategic partnerships with pharmaceutical companies. (Ongoing)
- Advancements in technological innovation to improve drug development efficiency. (Ongoing)
What Are the Key Risks for ROIVW?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trial outcomes for key drug candidates.
- Regulatory setbacks and delays in approval processes.
- Competition from established pharmaceutical companies and biosimilars.
- High R&D expenses and potential for cash burn.
- Dependence on strategic partnerships and collaborations.
What Are the Growth Opportunities for ROIVW?
- Expansion of Pipeline: Roivant has the opportunity to continue expanding its pipeline through strategic acquisitions and in-licensing agreements. By acquiring promising drug candidates that have been deprioritized by larger pharmaceutical companies, Roivant can leverage its expertise to advance these candidates through clinical development and regulatory approval. The market for repurposed drugs and novel therapies is substantial, offering significant growth potential for Roivant. Timeline: Ongoing.
- Strategic Partnerships: Roivant can pursue strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its drug candidates. These partnerships can provide Roivant with access to additional resources, expertise, and distribution channels, accelerating the commercialization process and maximizing the market potential of its products. The market for pharmaceutical collaborations is robust, with numerous opportunities for Roivant to forge mutually beneficial partnerships. Timeline: Ongoing.
- Technological Innovation: Roivant can leverage technological innovation to improve the efficiency and effectiveness of its drug development process. By investing in advanced technologies such as artificial intelligence and machine learning, Roivant can accelerate drug discovery, optimize clinical trial design, and personalize treatment approaches. The market for AI-driven drug discovery is rapidly growing, offering significant opportunities for Roivant to gain a competitive edge. Timeline: Ongoing.
- Geographic Expansion: Roivant can expand its geographic presence by entering new markets and establishing operations in key regions around the world. By expanding its geographic reach, Roivant can access new patient populations and increase its market share. The global market for pharmaceuticals is vast, with significant opportunities for Roivant to expand its presence in emerging markets. Timeline: 2027-2030.
- Regulatory Approvals: Roivant's growth is heavily dependent on securing regulatory approvals for its drug candidates. Successful clinical trial outcomes and positive regulatory decisions can significantly increase the value of Roivant's pipeline and drive revenue growth. The market for approved therapies is substantial, with significant opportunities for Roivant to generate revenue from its commercialized products. Timeline: Ongoing.
What Are ROIVW's Competitive Advantages?
- Diversified Pipeline: Roivant's diversified pipeline of drug candidates across multiple therapeutic areas reduces its reliance on a single product or indication.
- Hub-and-Spoke Model: Roivant's unique organizational structure allows for specialized expertise and focused development efforts across its 'Vant' companies.
- Strategic Acquisitions: Roivant's ability to acquire and develop promising drug candidates from other companies provides it with a competitive advantage.
- Strong Intellectual Property: Roivant's portfolio of patents and other intellectual property rights protects its drug candidates and provides it with a competitive edge.
What Does ROIVW Do?
Roivant Sciences Ltd. was established in 2014 with the mission of accelerating the development and commercialization of promising drug candidates. The company operates under a unique hub-and-spoke model, creating multiple 'Vant' companies, each focused on specific therapeutic areas or technologies. This decentralized structure allows for specialized expertise and focused development efforts. Roivant's pipeline includes product candidates targeting solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. Roivant's approach involves acquiring or in-licensing drug candidates that have been deprioritized by larger pharmaceutical companies, and then applying its expertise and resources to advance these candidates through clinical development and regulatory approval. The company's headquarters are located in London, United Kingdom, and it employs approximately 620 individuals. Roivant aims to improve the efficiency of drug development and deliver innovative medicines to patients in need.
What Products and Services Does ROIVW Offer?
- Develops and commercializes pharmaceutical products.
- Focuses on multiple therapeutic areas, including oncology and dermatology.
- Acquires and develops drug candidates that have been deprioritized by larger companies.
- Utilizes a hub-and-spoke model with multiple 'Vant' companies.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approvals from agencies such as the FDA and EMA.
- Aims to improve the efficiency of drug development.
How Does ROIVW Make Money?
- Acquires or in-licenses drug candidates from other companies.
- Develops and conducts clinical trials for these drug candidates.
- Seeks regulatory approval for its products.
- Commercializes and markets approved drugs, either independently or through partnerships.
What Industry Does ROIVW Operate In?
Roivant Sciences operates within the biotechnology industry, a sector characterized by high growth potential and significant investment in research and development. The industry is driven by increasing demand for innovative therapies and advancements in medical technology. Roivant's hub-and-spoke model differentiates it from traditional pharmaceutical companies, allowing for greater agility and specialization. The company faces competition from established pharmaceutical companies and other biotechnology firms, including ABCM, ALPN, BPMC, CERE, and IMGN, all vying for market share in various therapeutic areas.
Who Are ROIVW's Key Customers?
- Patients suffering from various diseases and conditions.
- Healthcare providers who prescribe Roivant's medications.
- Hospitals and clinics that administer Roivant's therapies.
- Pharmaceutical companies that partner with Roivant on drug development and commercialization.
Company Profile
Roivant Sciences Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Matthew Gline. ROIVW has traded publicly since 2021.
Financial Health
Roivant Sciences Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.30 places it in the safe zone, indicating low near-term bankruptcy risk.
ROIVW Financials
Bull Case vs Bear Case
Bull Case
- Innovative hub-and-spoke business model.
- Diversified pipeline of drug candidates.
- Strong gross margin potential.
- Experienced management team.
Bear Case
- Negative P/E ratio and profit margin.
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- High R&D expenses.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
ROIVW Latest News
No recent news available for ROIVW.
ROIVW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ROIVW.
Price Targets
Wall Street price target analysis for ROIVW.
ROIVW MoonshotScore
What does this score mean?
The MoonshotScore rates ROIVW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Matthew Gline
CEO
Matthew Gline serves as the CEO of Roivant Sciences, bringing extensive experience in the biopharmaceutical industry. Prior to joining Roivant, Gline held leadership positions at several healthcare companies, where he focused on corporate strategy, business development, and financial management. His background includes a strong understanding of drug development, regulatory affairs, and commercialization strategies. Gline's expertise is instrumental in guiding Roivant's strategic direction and driving its growth initiatives.
Track Record: Under Matthew Gline's leadership, Roivant Sciences has expanded its pipeline through strategic acquisitions and partnerships. He has overseen the advancement of several drug candidates through clinical development, achieving key milestones and regulatory submissions. Gline has also focused on fostering a culture of innovation and collaboration within Roivant, attracting top talent and driving the company's mission of improving healthcare outcomes.
What Investors Ask About Roivant Sciences Ltd. (ROIVW) — Healthcare
What does Roivant Sciences Ltd. do?
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company focused on accelerating the development and commercialization of innovative medicines. The company operates through a hub-and-spoke model, creating multiple 'Vant' companies that focus on specific therapeutic areas or technologies.
What do analysts say about ROIVW stock?
Analyst coverage of Roivant Sciences Ltd. (ROIVW) is pending, with evaluations focusing on the company's pipeline progress, clinical trial outcomes, and regulatory milestones. Key valuation metrics include market capitalization, revenue potential from approved therapies, and R&D spending. Growth considerations involve the company's ability to expand its pipeline, secure strategic partnerships, and achieve successful commercialization of its products. Investors should monitor analyst reports for updates on Roivant's performance and future prospects.
What are the main risks for ROIVW?
Roivant Sciences Ltd. faces several risks inherent to the biotechnology industry. These include the potential for unsuccessful clinical trial outcomes, regulatory setbacks and delays, competition from established pharmaceutical companies and biosimilars, high R&D expenses, and dependence on strategic partnerships and collaborations. The company's financial performance is also subject to market volatility and macroeconomic factors. Investors should carefully consider these risks when evaluating Roivant's investment potential.
What are the key factors to evaluate for ROIVW?
Evaluate ROIVW on fundamentals, analyst consensus, and risk factors. Roivant Sciences presents a compelling investment thesis based on its diversified pipeline and innovative business model. Not financial advice.
How frequently does ROIVW data refresh on this page?
ROIVW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ROIVW's recent stock price performance?
Roivant Sciences Ltd. (ROIVW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative hub-and-spoke business model. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ROIVW overvalued or undervalued right now?
Roivant Sciences Ltd. (ROIVW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ROIVW before investing?
Before investing in Roivant Sciences Ltd. (ROIVW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Analyst opinions are pending and subject to change.